Kirby McInerney LLP said it is investigating possible federal securities law violations after Alnylam reduced projected 2026 TTR net product revenue by about $200 million.
Kirby McInerney LLP said it has opened an investigation on behalf of Alnylam Pharmaceuticals, Inc. investors over possible violations of the federal securities laws or other unlawful business practices. The announcement followed Alnylam’s July 30, 2026 release of second-quarter 2026 results, when the company said it had lowered full-year 2026 TTR product sales guidance to reflect early launch learnings in the evolving ATTR-CM market and the normalization of second-line volume growth after pent-up demand from patients waiting for a new therapy had been met. Alnylam consequently reduced its projected total TTR net product revenue by approximately $200 million. Its shares then fell as much as $81.25, or 28.35%, in intraday trading on July 30, 2026, according to an earlier law firm statement, and closed down $81.14, or about 28%, at $205.48, according to Kirby McInerney LLP.